“Clinical research is really the only opportunity we have to give our patients some hope and some perspective that their disease will one day be treatable.” Nadege Gunn, MD, CPI, has consistently championed community engagement and physician referrals to drive successful clinical trial enrollment at her site in Waco, TX. As a MASH CARE Council … Read more
Velocity recently asked some key employees to come together and discuss a wide array of issues impacting diversity, equity, and inclusion (DEI) in trials. Velocity’s ongoing goals are to share best practices, identify and address shortcomings, and bring as many perspectives and viewpoints to the table as possible to advance clinical trials and deliver vital … Read more
To celebrate the upcoming Clinical Trials Day and the ‘Trailblazers Among Us’ theme, Paul Evans, President and CEO of Velocity, and Victoria DiBiaso, Head, Patient Informed Development & Health Value Translation at Sanofi, have coauthored this article. In the post, they review several of the opportunities and challenges inherent in shaping a better future for … Read more
Shishir Khetan, MD, is a Principal Investigator and Senior Medical Director at Velocity. He’s also a leading expert for the Cardiometabolic CARE Council. But as he explains in this video, he’s excited about the opportunities the CARE Council model is creating for investigators. Through expert knowledge exchange — including mentoring and training opportunities provided by … Read more
Heart disease remains the leading cause of death worldwide. The proliferation of heart issues — paired with lifestyle factors that complicate patient recruitment and study design — reflect an urgent need for expert-led clinical trials. Moreover, intersections among heart health and metabolic research offer promising opportunities to confront diseases affecting a growing, aging population, and … Read more
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising. In light of the stark unmet needs in liver disease treatment — particularly for metabolic dysfunction-associated steatohepatitis (MASH) — there’s a pressing need for more sites equipped to effectively support advanced liver disease research. As Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, mentions … Read more
Velocity recently asked some key employees to come together and discuss a wide array of issues impacting diversity, equity, and inclusion (DEI) in clinical trials. Velocity’s ongoing goals are to share best practices, identify and address shortcomings, and bring as many perspectives and viewpoints to the table as possible to advance clinical trial science and … Read more
Évelyne Newton and Sylwia Kołodziej recently made the journey overseas to join our CARE Council summit in Durham, NC. Along with dozens of our physicians and operational, commercial, and recruitment leaders, they helped define a strategy to extend the reach of new and existing CARE Councils. As they mention in this video, by enhancing the … Read more
Last month, Nick Spittal, Velocity’s chief operating officer announced the company’s latest partnership with HealthMatch and results from an unprecedented patient recruitment pilot at the SCOPE conference in Orland, Florida. He was joined by HealthMatch CEO, Manuri Gunawardena, on stage for a joint presentation, as Clinical Trials Report journalist Michael Causey reports: Velocity announced its … Read more
Despite a boom in tech funding and monumental advancements in AI/ML and in silico models, tech advancements have not yet translated into marked efficiency improvements at clinical research sites. Most clinical trials still fail to meet enrollment timelines, with most delays occurring at the site level. To gain efficiency, technology must enhance clinical trials at … Read more